Is Reserve Meds right for your situation?

On pricing. We do not publish drug-specific list prices. Every case is quoted individually, and the quote covers manufacturer list, documented duty at destination, cold-chain logistics, and our coordination fee. For indicative ranges by therapy category, see what to expect on cost. For a case-specific quote, begin a consultation.

Reserve Meds is a narrow service. We are a named-patient coordination platform operating a luxury-concierge service layer for named-patient cross-border access into a defined set of countries. We are not a clearinghouse, we are not a retail pharmacy, and we do not try to be everything to everyone. The fastest way to know whether we can help is to walk through four questions below. If every answer is yes, we are probably a good fit. If any answer is no, the rest of this page tells you exactly who to call instead.

First question: is your prescriber engaged?

Our entire model assumes that a licensed physician has already examined the patient, made a diagnosis, and chosen a therapy. We are the coordinator between that prescriber and a US supply chain; we are not a substitute for that prescriber, and we do not issue prescriptions ourselves. If the patient does not yet have a treating physician for the indication in question, or if the current physician has not committed to the therapy in writing, stop here. The first step is not to contact us. The first step is to have a clear conversation with the treating physician, get a written prescription or a medical-necessity letter, and align on what the plan of care will look like over the coming months. Once that is in hand, come back to us.

If the prescriber has agreed to the therapy and is willing to sign the paperwork a named-patient program requires, we can take the coordination burden off their desk. What we cannot do is persuade a physician to prescribe something they have not independently concluded is right for the patient. That boundary is both an ethical one and a regulatory one, and we hold it firmly.

Second question: is the drug FDA-approved or FDA-cleared?

Our lane is US-sourced medicines with a current FDA approval or clearance. That covers a wide surface area: specialty oncology, rare-disease biologics, gene and cell therapies, advanced immunology and neurology drugs, and a growing roster of precision-medicine products. What it does not cover is investigational agents that remain in clinical trial, compounded formulations, products sourced outside the US, or therapies available only under an Expanded Access protocol at the manufacturer. If the drug your prescriber has in mind is not yet FDA-approved, the correct pathway is almost always the manufacturer's Expanded Access or compassionate-use program, which a treating physician initiates directly with the sponsor. We are happy to tell you whether a specific therapy sits in our lane; a short note to our consultation desk is the quickest way to get a direct answer.

One additional boundary: we do not handle DEA-scheduled controlled substances under any circumstance. That exclusion is categorical and it applies whether the destination country treats the drug as controlled or not.

Third question: is the destination country one we operate into?

We coordinate supply into roughly forty countries, with a front-line concentration in the United Arab Emirates, the Kingdom of Saudi Arabia, India, Pakistan, and Egypt. Our capability falls off sharply outside that set, and there are jurisdictions where the named-patient pathway is either closed for the indication in question or not worth the timeline. If the patient is resident in a country that appears on our coverage map, we can typically execute. If the destination is outside our map, or if the specific indication-country combination is known-restricted, we will tell you candidly at intake and point you toward a local specialist. We would rather lose a case at the front door than fail one at customs.

Fourth question: can the family prepay?

Reserve Meds is a cash-pay service. We do not bill insurance, we do not process Medicare or Medicaid claims, and we do not take payment from payer networks on the patient's behalf. The therapies we coordinate are specialty-tier, which means unit costs for a single course can run from mid-five figures to low seven figures depending on modality. Families who proceed with us have typically already spoken with private wealth advisors, family offices, or foundations, and have either cash on hand or a committed financing source. If the family cannot prepay, we are almost certainly not the right coordinator. In that situation, the better path is the manufacturer's patient-assistance program, a disease-specific foundation, or an NPP facilitator operating on a lower-margin European-cost-basis model.

If any answer is "no," here is who to call instead

If the prescriber is not yet engaged, the call is to the treating hospital or clinic, not to us. Ask for a referral to a specialist in the relevant indication, and ask that specialist to document the therapy choice in writing. If the drug is investigational, the call is to the manufacturer's medical information line; ask specifically about Expanded Access or compassionate-use eligibility. If the destination country is outside our coverage map, search for a local named-patient coordinator licensed and regulated in that country; we are happy to share publicly known peer organizations on request. If the family cannot prepay, the call is to the manufacturer's patient-assistance program first, then to disease-specific foundations such as the relevant rare-disease patient organization, and finally to non-profit NPP facilitators that operate on different economics than we do.

If every answer is "yes"

Then we can probably help, and the next step is short. Use the consultation button below, describe the case in a paragraph or two, attach what the prescriber has already written, and we will come back to you within one business day with an honest assessment. We decline about one case in six at intake, usually because of a regulatory feasibility issue or a sourcing constraint rather than anything about the patient. When we decline, we say so quickly and point you to a better pathway. For more on our decline posture, see when we decline, and why.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.